mb 1 vs glp 1 GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders Arrae MB Frontiers | Clinical perspectives on

JiCXueGFLijunCFengPLiDLiLet al

List of adverse reactions of SSIBs included in this study

Clinical Application Guidance: Therapeutic selection should be individualized based on patient-specific factors, such as cardiovascular status, renal function, administration route preferences, and tolerability, with ongoing attention to emerging evidence to refine treatment strategies

Location: Plainsboro, New JerseyWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Wegovy (semaglutide) injection, for subcutaneous use, Ozempic (semaglutide) injection, for subcutaneous use, and Victoza (liraglutide) injection, for subcutaneous use.FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Novo Nordisk promoted Wegovy, Ozempic, and Victoza in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner

Unpleasant Side Effects The side effects of GLP-1 RAs are primarily gastrointestinal, and often include nausea, vomiting, diarrhea, bloating, and belching